UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL						
OMB Number:	3235-0287					
Estimated average burden						
nours per response						

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person *				2. I	2. Issuer Name and Ticker or Trading Symbol						5. Rel	5. Relationship of Reporting Person(s) to Issuer					
CATLIN AVERY W					Corbus Pharmaceuticals Holdings, Inc. [CRBP]							(Check all applicable)X_ Director10% Owner					
(Last) (First) (Middle) C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 100 RIVER RIDGE DRIVE				05/1	3. Date of Earliest Transaction (Month/Day/Year) 05/11/2017							officer (g	give title belo	w) (Other (specify b	elow)	
(Street) NORWOOD, MA 02062			4. If	4. If Amendment, Date Original Filed(Month/Day/Year)							_X_ For	6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					Table I - Non-Derivative Securities Acqui						uired, D	ired, Disposed of, or Beneficially Owned					
1.Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Year)	Execu ay/Year) any		Code (Instr. 8)	tion 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Beneficially Owned Following Reported Transaction(s)		Following n(s)	Ownership Form:	7. Nature of Indirect Beneficial				
				(Mont	th/Day/Y	ear)	Code	V	Amount	(A) or (D)	Price	Ì	(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
Common	Stock		05/11/2017				Р		5,000	A	\$ 6.148	47,0	00			D	
Reminder: indirectly.	Report on a	separate line	for each class of se	curities	beneficia	ılly											
								con	tained i	n this f	orm a	are not	requi	ired to re	formation spond unl itrol numb	ess	EC 1474 (9- 02)
			Table II -				es Acquiro						vned				
Security	Conversion	3. Transactic Date (Month/Day	Execution I (Year) any	d Date, if			5. Number of	6. I	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. A ¹ U ¹ Se (Ir	7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction ((Instr. 4)	Ownership Form of Derivative Security: Direct (D) or Indirect) [`
					Code	V	(A) (D)	Dat Exe	e ercisable	Expirati Date	ion Ti	Amo or tle Num of Shar	nber				
Repor	ting O	wners															

Booking Occupy Name (Addison	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
CATLIN AVERY W C/O CORBUS PHARMACEUTICALS HOLDINGS, INC 100 RIVER RIDGE DRIVE NORWOOD, MA 02062	X					

Signatures

/s/ Avery Catlin	05/12/2017
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.